News & Events

HMN 2026: How KRAS(ON) inhibitor zoldonrasib showed effective, durable responses in patients with advanced G12D-mutated lung cancer

HMN 2026: How KRAS(ON) inhibitor zoldonrasib showed effective, durable responses in patients with advanced G12D-mutated lung cancer

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

Elisrasib Shows Clinical Benefit in KRAS G12C Lung Cancer

Elisrasib Shows Clinical Benefit in KRAS G12C Lung Cancer

Title: Elisrasib Shows Clinical Benefit in Advanced NSCLC with KRAS G12C Mutation After Prior Therapy Failure

Title: Elisrasib Shows Clinical Benefit in Advanced NSCLC with KRAS G12C Mutation After Prior Therapy Failure

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

AURKA/PHB2 Signaling Fuels Resistance to KRAS G12C Inhibitors

AURKA/PHB2 Signaling Fuels Resistance to KRAS G12C Inhibitors

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

Fawzi Abu Rous: Turning KRAS From “Undruggable” to a Targetable Driver in NSCLC

Fawzi Abu Rous: Turning KRAS From “Undruggable” to a Targetable Driver in NSCLC

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC